글로벌 아로마타제 결핍 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모                              

아로마타제 결핍증은 호르몬 불균형으로 특징지어지며, 이는 낮은 에스트로겐 수치와 높은 테스토스테론 수치로 인해 성적 발달과 성숙을 방해합니다. 유전적으로 여성인 아기(X 염색체가 두 개 있음)는 종종 생식기가 여성 또는 남성인지 확실히 구별되지 않는 경우가 많습니다(모호한 생식기라고 함). 그들의 생식 기관은 일반적으로 정상이지만, 환자는 어린 시절에 난소 낭종이 생길 수 있으며, 유방 성장과 생리는 청소년기에 영향을 받을 수 있습니다. 고환이 작거나 내려오지 않은 남성은 삶의 후반에야 발견되는 경우가 드뭅니다. 남성은 또한 성적 욕망 부족, 정자 생산 부족, 불임 또는 뼈 약화로 고통받을 수 있습니다.

Data Bridge Market Research는 아로마타제 결핍증 시장이 2021년에 9,045만 달러 규모였으며 2029년까지 1억 935만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 2.40%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

 Aromatase deficiency is an uncommon condition that affects the synthesis of estradiol, causing hirsutism in pregnant women, pseudohermaphroditism and virilization in women, and tall height, osteoporosis, and obesity in men. Female patients may be candidates for surgical genitalia modification depending on the degree of ambiguity, and ovarian cysts must be monitored. After puberty, daily estrogen treatment (0.625 mg/twice weekly increasing to daily) is required, which can be augmented with progesterone-like hormone and monthly gonadotrophin-releasing hormone antagonist therapies. Adult men should begin treatment as soon as possible after being diagnosed, with daily transdermal delivery of up to 50 g of estradiol for 6-9 months to complete skeletal development. Estradiol replacement may be lowered to 25 g per day after epiphyseal closure. Calcium, vitamin D, and physical activity should be included to a low-calorie diet. Symptomatic treatment is required for dyslipidemia, insulin resistance and glucose intolerance.

Aromatase Deficiency Market Dynamics

Drivers

• Rise in the number of cases of aromatase deficiency

The surging number of cases of aromatase deficiency is a major factor driving the market's growth rate during the forecast period of 2022-2029. Aromatase deficiency is a sexual development condition characterized by low estrogen levels and high testosterone leels. Because of excessive growth of long bones in the arms and legs, affected people are abnormally tall. The aberrant bone growth causes slower mineralization and bone thinning, which can result in bone fractures with little impact.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of aromatase deficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of aromatase deficiency market. Along with this, favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the aromatase deficiency market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the aromatase deficiency market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment as well as diagnosis will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the aromatase deficiency market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This aromatase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aromatase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Aromatase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Aromatase Deficiency Market Scope

The aromatase deficiency market is segmented on the basis of diagnosis, treatment, route of administration, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Physical Examination
• Gene Sequencing
• Genetic testing
• Others

Treatment

• Surgery
• Estrogen Replacement
• Others

Age of Onset

• Pediatrics
• Adults
• Geriatrics

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Aromatase Deficiency Market Regional Analysis/Insights

The aromatase deficiency market is analysed and market size insights and trends are provided by country, diagnosis, treatment, route of administration, age of onset, end-users and distribution channel as referenced above.

The countries covered in the aromatase deficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the aromatase deficiency market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of aromatase deficiency and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Aromatase Deficiency Market Share Analysis

The aromatase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aromatase deficiency market.

Some of the major players operating in the aromatase deficiency market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• 엘리 릴리 앤드 컴퍼니(미국)
• 머크앤코(미국)
• 알러간(아일랜드)
• 애벗(미국)
• 머크 KGaA(독일)
• Novo Nordisk A/S(덴마크)
• 제넨텍 주식회사(미국)
• 암젠 주식회사(미국)
• 엔도 인터내셔널 주식회사(아일랜드)
• 히사미츠제약 주식회사(일본)

SKU-68374